Official Title
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Brief Summary

Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Detailed Description

N/A for expanded access

Temporarily not available
Individual Patients
Treatment IND/Protocol
Non Small Cell Lung Cancer
Medullary Thyroid Cancer
Colon Cancer
Breast Cancer
Pancreatic Cancer
Papillary Thyroid Cancer
Other Solid Tumors With Evidence of Activating RET Alteration

Drug: Selpercatinib
Open-label expanded access
Other Name: LOXO-292
Other Name: LY3527723

Eligibility Criteria

Inclusion Criteria: - Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib - Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy - Have adequate organ function

Exclusion Criteria: - Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor - Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds

Eligibility Gender
Eligibility Age
Minimum: 18 Years
Hong Kong
New Zealand
United States

Cancer Treatment Centers of America
Goodyear, Arizona, 85338

Mayo Clinic of Scottsdale
Scottsdale, Arizona, 85259

City of Hope National Medical Center
Duarte, California, 91010

University of California - San Diego
La Jolla, California, 92103

UCLA Medical Center
Los Angeles, California, 90095

Kaiser Permanente
Oakland, California, 94612

Irvine Medical Center
Orange, California, 92868

Kaiser Permanente Medical Center
Sacramento, California, 94814

Kaiser Permanente Medical Center
San Francisco, California, 94115

Univ of California San Francisco
San Francisco, California, 94115

Kaiser Permanente
Santa Clara, California, 95051

UCLA Medical Center
Santa Monica, California, 90404

Kaiser Permanente Medical Center
Vallejo, California, 94589

Memorial Cancer Institute
Hollywood, Florida, 33021

Mayo Clinic-Jacksonville
Jacksonville, Florida, 32224

Florida Hospital
Orlando, Florida, 32803

Tallahassee Memorial Hospital
Tallahassee, Florida, 32308

University Cancer and Blood Center
Athens, Georgia, 30607

Emory University
Atlanta, Georgia, 30329

University of Chicago Medicine-Comprehensive Cancer Center
Chicago, Illinois, 60637

Cancer Treatment Centers of America, Chicago
Zion, Illinois, 60099

Massachusetts General Hospital
Boston, Massachusetts, 02114

Dana-Farber Cancer Institute
Boston, Massachusetts, 02215

University of Michigan
Ann Arbor, Michigan, 48109

START Midwest
Grand Rapids, Michigan, 49546

Mayo Clinic
Rochester, Minnesota, 55905

Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169

Memorial Sloan Kettering Cancer Center
New York, New York, 10065

Cleveland Clinic Foundation
Cleveland, Ohio, 44195

Ohio State University Medical Center
Columbus, Ohio, 43210

Cancer Treatment Centers of America
Tulsa, Oklahoma, 74133

University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104

Eastern Regional Medical Center
Philadelphia, Pennsylvania, 19124

Oncology Consultants
Houston, Texas, 77030

University of Texas MD Anderson Cancer Center
Houston, Texas, 77030

Virginia Cancer Specialists
Fairfax, Virginia, 22031

University of Wisconsin-Madison Hospital and Health Clinic
Madison, Wisconsin, 53792-4108

Contact Lilly at 1-800-LillyRx (1-800-545-5979)
Study Director
Eli Lilly and Company

Loxo Oncology, Inc.
Eli Lilly and Company
NCT Number
MeSH Terms
Thyroid Neoplasms
Thyroid Cancer, Papillary
Thyroid Diseases
Intervention Name